Topics Damages Pharma in Brief’s 2023 Year in Review and Trends for 2024The Ontario Superior Court dismisses a generic manufacturer’s claim for damages under section 8 of the PM(NOC) RegulationsSupreme Court denies leave to appeal in generic Statute of Monopolies case Intellectual property Pharma in Brief’s 2024 Year in Review and Trends for 2025Drug Pricing Update: PMPRB launches consultation on Draft Guidelines for price reviewFederal Court declares patent ineligible for listing during PM(NOC) infringement action Life sciences and healthcare Drug shortages: New requirements proposed for the Food and Drug RegulationsPharma in Brief’s 2024 Year in Review and Trends for 2025Drug Pricing Update: PMPRB launches consultation on Draft Guidelines for price review Pharmaceuticals and life sciences Canada expanding national pharmacare and rare disease drug coverageBritish Columbia becomes second province to sign pharmacare agreementAgile licensing, risk, biologics, and more: Wide-ranging amendments to Canada’s drug and medical device regulations Uncategorized CADTH advisory panel consults on framework for pan-Canadian formularyAmendments to the Federal Courts RulesFederal Court finds Minister of Health’s refusal to grant CSP based on the “Timely Submission Requirement” unreasonable
